Keywords
Wild type
Investigational new drug application
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To review the scientific literature on current evidence regarding the treatment of Wild-Type Gastrointestinal Stromal Tumors (GIST Wild Type). Methods: This is an integrative literature review based on the PICO strategy. Searches were conducted in the PubMed and BVS databases, including studies published between 2011 and 2024. From na initial total of 142 articles, 10 met the established inclusion criteria. Results: GIST Wild Type exhibits low responsiveness to standart first-line therapy for GIST due the absence of KIT and PDGFRA mutations. Its treatment depends on identifying molecular subtypes to guide targeted therapeutic strategies. There are no universally accepted protocols or therapies with confirmed efficacy for this subgroup. Final considerations: The reviewed literature emphasizes the lack of standardized and effective treatment approaches for GIST Wild Type. These findings underscore the urgent need for further molecular and clinical research to better understand the disease and to develop specific, evidence-based treatment strategies for affected patients.
References
AMI-BEN E, et al. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Ann Oncol, 2016; 27(9): 1794-9.
BLAKELY AM. Domar o tumor estromal gastrointestinal de tipo selvagem: cultura de tecido melhorada. Clin Cancer, 2022; 28(1): 3-4.
BLAY YJ, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol, 2020; 21(7): 923-34.
BRASIL. MOC: Manual de Oncologia Clínica Brasileira. São Paulo: 2020. Disponível em: https ://mocbrasil.com/moc-tumores-solidos/sarcomas-de-partes-moles/41-tumor-estromal-do-trato-gast rintestinal-gist. Acessado em: 27 mai. 2025.
CHUNG CCY, et al. Rare disease emerging as a global public health priority. Frontiers in Public Health. 2022; 10: 1028545.
FIORINO E, et al. Atividades antitumorais integradas da imunoterapia celular com linfócitos CIK e interferons contra GIST de tipo selvagem KIT/PDGFRA. Int J Mol Sci, 2022; 23: 10368.
GARRAFA V e PORTO D. Assistência às pessoas com doenças raras: um desafio ético, social e de equidade em saúde. Cadernos de Saúde Pública, 2020.
GLOD J, et al. A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor. Clin Cancer Res, 2019; 25(21): 6302-8.
HEINRICH MC, et al. Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol, 2017; 3(7): 944-52.
HUANG WK, et al. Terapia sistêmica para tumor estromal gastrointestinal: padrões atuais e desafios emergentes. Curr Treat Options Oncol, 2022; 23: 1303-19.
MARTIN-BROTO J, et al. REGISTRI: Regorafenib na primeira linha de GIST metastático de tipo selvagem KIT/PDGFRA: um ensaio colaborativo de fase II do Grupo Sarcoma Espanhol (GEIS), Italiano (ISG) e Francês (FSG). Mol Cancer, 2023; 22: 127.
MATHIAS-MACHADO MC, et al. Current Molecular Profile of Gastrointestinal Stromal Tumors and Systemic Therapeutic Implications. Cancers (Basel), 2022; 14(21): 5330.
MOGA DF, et al. Understanding Gastric GIST: From Pathophysiology to Personalized Treatment. Journal of Clinical Medicine. 2024; 13(14): 3997.
OLIVEIRA, R. C. et al. Epidemiologia dos tumores gastrointestinais no Brasil: análise de dados hospitalares. Revista de Medicina da USP, 2021.
RUTKIWSKI P, et al. The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study. BMC Cancer, 2012; 12: 107.
UPTODATE. EUA: 24 de maio de 2021. Disponível em: https ://www.uptodate.com/contents/clinical-presentation-diagnosis-and-prognosis-of-gastrointestinal-stromal-tumors. Acessado em: 27 mai. 2025.
VON MEHREN M, et al. Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study. Clin Cancer Res, 2020; 26(8): 1837-45.
WOJTARA M, et al. Artificial intelligence in rare disease diagnosis and treatment. Clinical and Translational Science. 2023; 16(11): 2106–2111.
ZHOU Y, et al. A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood. Cancer Med, 2020; 9(17): 6225-33.
ZHOU Y, et al. Artificial intelligence-assisted endoscopic ultrasonography for the diagnosis of gastrointestinal stromal tumors: a systematic review and meta-analysis. Endoscopy. 2023; 55(6): 522–530.